CLIF-C OFs在非乙型肝炎相关慢性肝病急性失代偿患者中鉴别慢加急性肝功能衰竭的临床研究

Clinical Study on CLIF-C OFs for Distinguishing Acute-on-chronic Liver Failure in Non-HBV-related ChronicLiver Disease with Acute Decompensation

背景:近期欧洲一项针对酒精和丙型肝炎肝硬化急性失代偿(AD)患者的前瞻性研究表明,慢性肝功能衰竭联-盟-器官功能衰竭评分(CLIF-C OFs)是区分慢加急性肝功能衰竭(ACLF)的有效诊断标准。目的:探讨CLIF-C OFs在非乙型肝炎相关慢性肝病并发AD患者中鉴别ACLF的有效性。方法:筛选并纳入2005年1月-2010年12月上海仁济医院非乙型肝炎相关慢性肝病AD患者274例,按CLIF-C OFs标准分为入院时ACLF组、入院28 d=ACLF组和非ACLF组。分析ACLF组和非ACLF组的临床和实验室指标、病情严重程度和短期死亡率。结果:入院时ACLF患者40例27例为人院28 d=ACLF组,非ACLF组207例。ACLF组TB、Cr、INR、ALT、AST、ALB、WBC、ChildPugh、CTP、MELD、MELD-Na评分均显著高于非ACLF患者(P<0.05),且年龄更轻(P<0.01)。ACLF组肝、肾、脑、凝血、循环、肺衰竭的发生率均显著高于非ACLF组(P<0.01),28 d和90 d死亡率均显著升高(P<0.001)。入院28 d=ACLF组上述指标与入院时ACLF组相比差异均无统计学意义(P>0.05)。入院时TB水平、28 d内合并感染为进展为ACLF的危险因素(P<0.05)。结论:非乙型肝炎相关慢性肝病并发AD患者中确实存在一群疾病程度更严重的ACLF群体,CLIF-C OFs标准可将ACLF患者从非乙型肝炎相关慢性肝病并发AD患者中区分出来。

Background：A recent perspective European study has shown that Chronic Liver Failure-Consortium Organ Failure score（CLIF-C OFs）is an effective diagnostic criteria for acute-on-chronic liver failure（ACLF）in alcoholic or hepatitis C virus patients with acute decompensation（AD）. Aims：To assess the efficacy of CLIF-C OFs for distinguishing ACLF in non-hepatitis B virus（HBV）-related chronic liver disease patients with AD. Methods：A total of 274 consecutive non-HBV-related chronic liver disease patients with AD from Jan. 2005 to Dec. 2010 at Shanghai Ren Ji Hospital were enrolled. Patients were divided into three groups：ACLF at admission,ACLF developed within 28-day and non-ACLF according to CLIF-C OFs criteria. Clinical and biochemistry characteristics,severity of the disease and 28-day and 90-day mortality data between ACLF and non-ACLF groups were analyzed. Results：Of the patients assessed,40 had ACLF at admission,27 had ACLF developed within 28-day,207 remained not having ACLF. Patients in ACLF group had higher TB,Cr,INR,ALT,AST,ALB,WBC,score of Child-Pugh,CTP,MELD,MELD-Na than non-ACLF patients（P〈0. 05）,and were younger in age（P〈 0. 01）. Incidences of hepatic,renal,cerebral,coagulation,circulation and lung failure,28-day mortality,90-day mortality were significantly higher in ACLF group than in non-ACLF patients（ P〈0. 01）. However,no significant differences were seen in the characteristics mentioned above between ACLF at admission group and ACLF developed at 28-day group（P〉 0. 05）. TB level at admission and infection occurred within 28-day were＆amp;nbsp;the risk factors for developing ACLF（P〈 0. 05）. Conclusions：ACLF constitutes a more severe subgroup in non-HBV-related chronic liver disease patients with AD,and CLIF-C OFs could help to distinguish ACLF patients out from non-HBV-related chronic liver disease patients with AD.